News for GKOS Stock

Glaukos Announces First Quarter 2025 Financial Results Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting Glaukos Announces the Release of its 2024 Sustainability Report Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30 RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™ Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20 Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform Glaukos Submits New Drug Application to U.S. FDA for Epioxa™ Glaukos Announces Participation in the J.P. Morgan Healthcare Conference Glaukos Announces Participation in Upcoming Investor Conferences Glaukos Announces Third Quarter 2024 Financial Results Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 Glaukos Announces Participation in Upcoming Investor Conferences Glaukos Announces Second Quarter 2024 Financial Results Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31 Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock Glaukos Announces Participation in Upcoming Investor Conferences Glaukos Announces First Quarter 2024 Financial Results Glaukos Announces the Release of its 2023 Sustainability Report Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1 Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant) Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21 Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance Glaukos Announces Participation in the J.P. Morgan Healthcare Conference Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant) Glaukos Announces Participation in Stifel Healthcare Conference Glaukos Announces Third Quarter 2023 Financial Results Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023 Glaukos Announces Participation in Wells Fargo Healthcare Conference Glaukos Announces Second Quarter 2023 Financial Results Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc. Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023 Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on) Glaukos Announces Participation in the William Blair Growth Stock Conference Glaukos Announces FDA Acceptance of NDA Submission for iDose TR Glaukos Announces First Quarter 2023 Financial Results Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting Glaukos Announces the Release of its 2022 Sustainability Report Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3 Glaukos Submits New Drug Application to U.S. FDA for iDose TR Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results Glaukos Announces Participation in the Citi Healthcare Conference Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22 Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability Glaukos Announces Participation in the J.P. Morgan Healthcare Conference Glaukos Announces Participation in the Stephens Annual Investment Conference Glaukos Corporation Announces Third Quarter 2022 Financial Results Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2 Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreement with Glaukos Corporation Glaukos Announces Participation in the Wells Fargo Healthcare Conference Glaukos Licenses Iveena’s Investigational Keratoconus Therapy Glaukos Corporation Announces Second Quarter 2022 Financial Results Glaukos Announces FDA 510(k) Clearance of iStent infinite® Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3 Glaukos Announces Participation in the William Blair Growth Stock Conference Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium Glaukos Corporation Announces First Quarter 2022 Financial Results Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting Glaukos Announces the Release of its 2021 Sustainability Report Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4 Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results Glaukos Announces Executive Leadership Changes Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22 Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease Glaukos Announces FDA 510(k) Clearance of iPRIME™ Glaukos Announces Participation in the J.P. Morgan Healthcare Conference Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director Glaukos Announces Participation in Upcoming Investor Conferences Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting Glaukos Corporation Announces Third Quarter 2021 Financial Results Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4 Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractive Surgeons Annual Meeting Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc. Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc. Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite™ Glaukos Announces Participation in the Wells Fargo Healthcare Conference Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent® Technologies Glaukos Corporation Announces Second Quarter 2021 Financial Results Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting Glaukos Corporation to Release Second Quarter 2021 Financial Results after Market Close on August 5 Glaukos Comments on the Centers for Medicare and Medicaid Services 2022 Proposed Physician Fee Schedule Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR Glaukos Announces Australia’s TGA Regulatory Approval for PRESERFLO™ MicroShunt Glaukos Announces Participation in the William Blair 41st Annual Growth Stock Conference Glaukos Expands its PRESERFLO™ MicroShunt Relationship with Santen via New License Agreement Glaukos Corporation Announces First Quarter 2021 Financial Results Glaukos Announces the Release of its 2020 Sustainability Report Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5 Glaukos to Support World Glaucoma Week with Patient Education Campaign and Free Screening Initiatives Glaukos Announces Participation in Oppenheimer Healthcare Conference Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results Glaukos Announces Positive Phase 3 Trial Results for iLink™ Epi-on Investigational Therapy That Met the Primary Efficacy Endpoint Glaukos Corporation to Release Fourth Quarter and Full Year 2020 Financial Results after Market Close on February 25 Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Sales Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study U.S. IDE Trial Results for Glaukos’ iStent infinite™ Show Substantial Reduction in IOP Glaukos Announces Participation in J.P. Morgan Healthcare Conference Glaukos Announces Participation in Upcoming Investor Conferences Glaukos Corporation Announces Third Quarter 2020 Financial Results Glaukos Corporation to Release Third Quarter 2020 Financial Results after Market Close on November 5